• New Therapy for
    Atrial Fibrillation

    Corhythm is an early stage company developing a novel therapy for the treatment of atrial fibrillation. More than three million Americans suffer from atrial fibrillation or a rapid, irregular heart rhythm. Atrial fibrillation is the most common cardiac arrhythmia and the leading cause of stroke and heart failure. While current therapies exist, none represent an ideal treatment due to limited efficacy and undesirable side effects.

    Learn More